Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
03 nov. 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023 - WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc....
Dyne Therapeutics to Present at Investor Conferences in November
02 nov. 2022 07h30 HE
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
31 oct. 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- Company Anticipates Reporting Data from Global, Multiple Ascending Dose DELIVER Clinical Trial in the Second Half of 2023 - WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics,...
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
11 oct. 2022 16h10 HE
|
Dyne Therapeutics, Inc.
- Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping - - First Presentation of In Vitro Data for...
Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
27 sept. 2022 07h30 HE
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event
12 sept. 2022 07h00 HE
|
Dyne Therapeutics, Inc.
- Presentation and Discussion with Two Leading Neuromuscular Disease Experts - - Data from DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Anticipated in the Second Half of 2023 - - Refined...
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
06 sept. 2022 16h30 HE
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
06 sept. 2022 07h01 HE
|
Dyne Therapeutics, Inc.
- First Patient Expected to be Dosed in September - - Data from Global, Multiple Ascending Dose ACHIEVE Trial Anticipated in the Second Half of 2023 - - Dyne to Host “Spotlight on the Clinic”...
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
06 sept. 2022 07h00 HE
|
Dyne Therapeutics, Inc.
- Data from Global, Multiple Ascending Dose DELIVER Trial Anticipated in the Second Half of 2023 - - Dyne to Host “Spotlight on the Clinic” Virtual Event on September 12 - WALTHAM, Mass., Sept. ...
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development
29 août 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- Appointment Expands Dyne’s Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:...